Detail akcie Rhythm Pharm online

Business Summary: Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Rhythm Pharmaceuticals Inc revenues increased 50% to $132.5M. Net loss applicable to common stockholders decreased 30% to $153.1M. Revenues reflect Biopharmaceutical segment increase from $62.3M to $132.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.60 to -$2.38.